Warburg leads $171m funding in Chinese anti-tumour drug maker HaiHe Biopharma

Warburg leads $171m funding in Chinese anti-tumour drug maker HaiHe Biopharma

Source: Volodymyr Hryshchenko/Unsplash

24 July, 2020

anti-tumour biopharmaceutical HaiHe Biopharma Warburg Pincus

Printed by Unregistered user on Tue, 22 Jul 2025 02:55:48 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

Fidelity leads $97m Series C round in Chinese biopharma Antengene

Junshi becomes first dual-listed biopharma firm after $692m STAR IPO

Read more from Greater China

Venture Capital

Startup funding in Greater China grows 13% in Q2 on Ximalaya’s $2.4b deal

Cannot rely solely on valuation metrics for AI investments: Cathay Innovation